Marshall Wace
RUBY

Marshall Wace’s Rubius Therapeutics, Inc RUBY Stock Holding History

Marshall Wace’s Portfolio RUBY Stock Details RUBY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-425,497
Closed -$184K – 3657
2022
Q3 		$184K Hold
425,497
– – ﹤0.01% 3105
2022
Q2 		$362K Sell
425,497
-26,008
-6% -$43.7K ﹤0.01% 2947
2022
Q1 		$2.49M Buy
+451,505
New +$2.87M ﹤0.01% 1919
2020
Q1 		– Sell
-11,681
Closed -$111K – 2188
2019
Q4 		$111K Buy
+11,681
New +$113K ﹤0.01% 1439
2019
Q2 		– Sell
-79,523
Closed -$1.44M – 1978
2019
Q1 		$1.44M Buy
+79,523
New +$1.22M 0.01% 832

Other funds holding RUBY

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return
SOMRS
State of Michigan Retirement System Lansing, Michigan $18.9B AUM 27.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Marshall Wace's RUBY Position: Q4 2022 in Review

Marshall Wace sold out of Rubius Therapeutics, Inc (RUBY) in Q4 2022, closing a stake of 425,497 shares — an estimated $184K sold.

Marshall Wace first reported a position in RUBY in Q1 2019 and held it in 5 quarters. The position peaked at $2.49M in Q1 2022. 42 funds tracked by Wall St. Rank hold RUBY as of Q4 2022.

  • Marshall Wace reported no remaining Rubius Therapeutics, Inc position as of Q4 2022 after selling out during the quarter.
  • Marshall Wace sold 425,497 Rubius Therapeutics, Inc shares in Q4 2022, an estimated $184K.
  • Marshall Wace first reported a position in Rubius Therapeutics, Inc in Q1 2019 and held it in 5 quarters.
  • Marshall Wace's Rubius Therapeutics, Inc position peaked at $2.49M in Q1 2022.
  • 42 funds tracked by Wall St. Rank held Rubius Therapeutics, Inc as of Q4 2022.

Based on Marshall Wace's 13F filing for Q4 2022, filed 14 Feb 2023.